TCM
KZIA

Traynor Capital Management’s Kazia Therapeutics KZIA Stock Holding History

Traynor Capital Management’s Portfolio KZIA Stock Details KZIA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-200
Closed -$4.3K – 316
2024
Q3 		$4.3K Buy
+200
New +$3.99K ﹤0.01% 281

Other funds holding KZIA

MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
AF
Allworth Financial Folsom, California $24.7B AUM 15.55% 1-Year Est. Return

Traynor Capital Management's KZIA Position: Q4 2024 in Review

Traynor Capital Management sold out of Kazia Therapeutics (KZIA) in Q4 2024, closing a stake of 200 shares — an estimated $4.3K sold.

Traynor Capital Management first reported a position in KZIA in Q3 2024 and held it in 1 quarter. The position peaked at $4.3K in Q3 2024. 10 funds tracked by Wall St. Rank hold KZIA as of Q4 2024.

  • Traynor Capital Management reported no remaining Kazia Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Traynor Capital Management sold 200 Kazia Therapeutics shares in Q4 2024, an estimated $4.3K.
  • Traynor Capital Management first reported a position in Kazia Therapeutics in Q3 2024 and held it in 1 quarter.
  • Traynor Capital Management's Kazia Therapeutics position peaked at $4.3K in Q3 2024.
  • 10 funds tracked by Wall St. Rank held Kazia Therapeutics as of Q4 2024.

Based on Traynor Capital Management's 13F filing for Q4 2024, filed 17 Jan 2025.